Definity Rt is a drug owned by Lantheus Medical Imaging Inc. It is protected by 10 US drug patents filed from 2021 to 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be May 04, 2037. Details of Definity Rt's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US11395856 | Lipid-encapsulated gas microsphere compositions and related methods |
Dec, 2035
(11 years from now) | Active |
| US10022460 | Lipid-encapsulated gas microsphere compositions and related methods |
Dec, 2035
(11 years from now) | Active |
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10588988 | Methods and devices for preparation of ultrasound contrast agents |
May, 2037
(12 years from now) | Active |
| US9789210 | Methods for making ultrasound contrast agents |
Mar, 2037
(12 years from now) | Active |
| US10583208 | Methods for making ultrasound contrast agents |
Mar, 2037
(12 years from now) | Active |
| US11529431 | Methods for making ultrasound contrast agents |
Mar, 2037
(12 years from now) | Active |
| US11857646 | Methods for making ultrasound contrast agents |
Mar, 2037
(12 years from now) | Active |
| US11266750 | Methods for making ultrasound contrast agents |
Mar, 2037
(12 years from now) | Active |
| US11925695 | Methods for making ultrasound contrast agents |
Mar, 2037
(12 years from now) | Active |
| US10583207 | Lipid-encapsulated gas microsphere compositions and related methods |
Dec, 2035
(11 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Definity Rt's patents.
Latest Legal Activities on Definity Rt's Patents
Given below is the list of recent legal activities going on the following patents of Definity Rt.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Email Notification Critical | 12 Mar, 2024 | US11925695 |
| Recordation of Patent Grant Mailed Critical | 12 Mar, 2024 | US11925695 |
| Recordation of Patent eGrant | 12 Mar, 2024 | US11925695 |
| Patent Issue Date Used in PTA Calculation Critical | 12 Mar, 2024 | US11925695 |
| Patent eGrant Notification | 12 Mar, 2024 | US11925695 |
| Mail Patent eGrant Notification | 12 Mar, 2024 | US11925695 |
| Email Notification Critical | 22 Feb, 2024 | US11925695 |
| Issue Notification Mailed Critical | 21 Feb, 2024 | US11925695 |
| Application Is Considered Ready for Issue Critical | 08 Feb, 2024 | US11925695 |
| Email Notification Critical | 08 Feb, 2024 | US11925695 |
US patents provide insights into the exclusivity only within the United States, but Definity Rt is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Definity Rt's family patents as well as insights into ongoing legal events on those patents.
Definity Rt's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Definity Rt's generic launch date based on the expiry of its last outstanding patent is estimated to be May 04, 2037 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Definity Rt Generics:
There are no approved generic versions for Definity Rt as of now.
Alternative Brands for Definity Rt
Definity Rt which is used for diagnostic ultrasound imaging., has several other brand drugs in the same treatment category and using the same active ingredient (Perflutren). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Lantheus Medcl |
| |||
About Definity Rt
Definity Rt is a drug owned by Lantheus Medical Imaging Inc. It is used for diagnostic ultrasound imaging. Definity Rt uses Perflutren as an active ingredient. Definity Rt was launched by Lantheus Medcl in 2001.
Approval Date:
Definity Rt was approved by FDA for market use on 31 July, 2001.
Active Ingredient:
Definity Rt uses Perflutren as the active ingredient. Check out other Drugs and Companies using Perflutren ingredient
Treatment:
Definity Rt is used for diagnostic ultrasound imaging.
Dosage:
Definity Rt is available in injectable form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 13.04MG/2ML (6.52MG/ML) | INJECTABLE | Prescription | INTRAVENOUS |